HRP20140705T1 - Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina - Google Patents
Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina Download PDFInfo
- Publication number
- HRP20140705T1 HRP20140705T1 HRP20140705AT HRP20140705T HRP20140705T1 HR P20140705 T1 HRP20140705 T1 HR P20140705T1 HR P20140705A T HRP20140705A T HR P20140705AT HR P20140705 T HRP20140705 T HR P20140705T HR P20140705 T1 HRP20140705 T1 HR P20140705T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- solvate
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title 1
- 108090000394 Erythropoietin Proteins 0.000 title 1
- 229940078467 Prolyl hydroxylase inhibitor Drugs 0.000 title 1
- -1 Triazolopyridine compound Chemical class 0.000 title 1
- 229940105423 erythropoietin Drugs 0.000 title 1
- 239000000411 inducer Substances 0.000 title 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 32
- 239000012453 solvate Substances 0.000 claims 32
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 9
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 6
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 claims 5
- 206010058116 Nephrogenic anaemia Diseases 0.000 claims 5
- 208000007502 anemia Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
Claims (34)
1. Spoj prikazan slijedećom formulom [I] ili njegova farmaceutski prihvatljiva sol ili njegov solvat:
[image]
u kojem je
parcijalna strukturna formula:
[image]
skupina koja je prikazana bilo kojom od slijedećih formula:
[image]
R1 je
atom vodika,
C1-6 alkil skupina,
C6-14 aril skupina,
C3-8 cikloalkil skupina,
C6-14 aril-C1-6alkil skupina, ili
C3-8 cikloalkil-C1-6alkil skupina;
R2 je
atom vodika,
C1-10 alkil skupina,
C6-14 aril skupina, opcijski supstituirana sa 1 do 5 istih ili različitih supstituenata izabranih iz slijedeće skupine B,
C3-8 cikloalkil skupina, opcijski supstituirana sa 1 do 5 istih ili različitih supstituenta izabranih iz slijedeće skupine B,
C3-8cikloalkenil skupina, opcijski supstituirana sa 1 do 5 istih ili različitih supstituenata izabranih iz slijedeće skupine B,
heteroaril skupina, opcijski supstituirana sa 1 do 5 istih ili različitih supstituenata izabranih iz slijedeće skupine B (gdje heteroaril ima osim ugljikovog atoma, 1 do 6 heteroatoma izabranih od atoma dušika, atoma kisika i atoma sumpora),
C6-14 aril-C1-6alkil skupina (gdje C6-14 aril je opcijski supstituiran sa 1 do 5 istih ili različitih supstituenata izabranih iz slijedeće skupine B) ili
C3-8cikloalkil-C1-6 alkil skupina (gdje C3-8 cikloalkil je opcijski supstituiran sa 1 do 5 istih ili različitih supstituenata izabranih iz slijedeće skupine B);
R3 je
atom vodika,
atom halogena
C1-6 alkil skupina,
C6-14 aril skupina,
C3-8 cikloalkil skupina,
C6-14 aril-C1-6alkil skupina, i
R4 i R5 su svaki nezavisno
atom vodika, ili
C1-6 alkil skupina,
skupina B:
atom halogena
C1-6 alkil skupina
C3-8cikloalkil skupina
cijano skupina, i
halo-C1-6alkil skupina.
2. Spoj prema patentnom zahtjevu 1, u kojem je parcijalna strukturna formula
[image]
skupina prikazana slijedećom formulom
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
3. Spoj prema zahtjevu 1, u kojem je parcijalna strukturna formula
[image]
skupina prikazana slijedećom formulom
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
4. Spoj prema patentnom zahtjevu 1, u kojem je parcijalna strukturna formula:
[image]
skupina prikazana slijedećom formulom
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
5. Spoj prema patentnom zahtjevu 1, u kojem je parcijalna strukturna formula:
[image]
skupina prikazana slijedećom formulom
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, u kojem su oba R4 i R5 atomi vodika, ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, u kojem je R3 atom vodika, ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, u kojem je R1 atom vodika, ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, u kojem je R2
C1-10 alkil skupina,
C6-14 aril skupina opcijski supstituirana sa 1 do 5 istih ili različitih supstituenata izabranih iz gore navedene skupine B,
C6-14 aril-C1-6alkil skupina (gdje C6-14 aril je opcijski supstituiran sa 1 do 5 istih ili različitih supstituenata izabranih iz gore navedene skupine B) ili
C3-8cikloalkil-C1-6 alkil skupina (gdje C3-8 cikloalkil je opcijski supstituiran sa 1 do 5 istih ili različitih supstituenata izabranih iz gore navedene skupine B), ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
10. Spoj prema patentnom zahtjevu 2, u kojem su oba R4 i R5 vodikovi atomi ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
11. Spoj prema patentnom zahtjevu 10, u kojem je R3 atom vodika, ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
12. Spoj prema patentnom zahtjevu 11, u kojem je R1 atom vodika, ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
13. Spoj prema patentnom zahtjevu 12, u kojem je R2
C1-10 alkil skupina, ili
C6-14 aril-C1-6 alkil skupina (gdje C6-14 aril je opcijski supstituiran sa 1 do 5 istih ili različitih supstituenata izabranih iz gore navedene skupine B),
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
14. Spoj prema patentnom zahtjevu 1, prikazan slijedećom formulom [I-1], ili njegova farmaceutski prihvatljiva sol ili njegov solvat
[image]
u kojem je parcijalna strukturna formula:
[image]
skupina prikazana bilo kojom od slijedećih formula:
[image]
R11 je
atom vodika,
C1-6 alkil skupina,
fenil skupina,
C3-8 cikloalkil skupina,
fenil-C1-6 alkil skupina, ili
C3-8 cikloalkil-C1-6alkil skupina, ili
R21 je
atom vodika,
C1-10alkil skupina,
fenil skupina opcijski supstituirana sa 1 do 5 istih ili različitih supstituenata izabranih iz slijedeće skupine B,
C3-8 cikloalkil skupina,
C3-8 cikloalkenil skupina,
tienil skupina opcijski supstituirana sa 1 do 5 istih ili različitih supstituenata izabranih iz slijedeće skupine B;
fenil-C1-6 alkil skupina (gdje je fenil opcijski supstituiran sa 1 do 5 istih ili različitih supstituenata izabranih iz slijedeće skupine B), ili
C3-8 cikloalkil-C1-6alkil skupina,
R31 je
atom vodika,
atom halogena,
C1-6 alkil skupina,
fenil skupina,
C3-8 cikloalkil skupina, ili
fenil-C1-6alkil skupina, i
R41 i R51 su svaki nezavisno
vodikov atom ili
C1-6alkil skupina,
skupina B:
atom halogena,
C1-6 alkil skupina,
C3-8cikloalkil skupina,
cijano skupina, i
halo-C1-6alkil skupina.
15. Spoj prema patentnom zahtjevu 1 prikazan slijedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
16. Spoj prema patentnom zahtjevu 1 prikazan slijedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
17. Spoj prema patentom zahtjevu 1 prikazan slijedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
18. Spoj prema patentom zahtjevu 1 prikazan slijedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
19. Spoj prema patentom zahtjevu 1 prikazan slijedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
20. Spoj prema patentom zahtjevu 1 prikazan slijedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
21. Spoj prema patentnom zahtjevu 1 prikazan slijedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
22. Spoj prema patentnom zahtjevu 1 prikazan slijedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
23. Spoj prema patentnom zahtjevu 1 prikazan slijedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
24. Spoj prema patentom zahtjevu 1 prikazan slijedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
25. Spoj prema patentom zahtjevu 1 prikazan slijedećom formulom:
[image]
ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
26. Farmaceutski sastav koji sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegovu farmaceutski prihvatljivu sol ili njegov solvat i farmaceutski prihvatljiv nosač.
27. Terapeutsko sredstvo za primjenu u liječenju anemije koje sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 25 ili njegovu farmaceutski prihvatljivu sol ili njegov solvat.
28. Terapeutsko sredstvo za primjenu u liječenju bubrežne anemije koje sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegovu farmaceutski prihvatljivu sol ili njegov solvat.
29. Upotreba spoja prema bilo kojem od patentnih zahtjeva 1 do 25 ili njegove farmaceutski prihvatljive soli ili njegovog solvata, u proizvodnji terapeutskog sredstva protiv anemije.
30. Upotreba spoja prema bilo kojem od patentnih zahtjeva 1 do 25 ili njegove farmaceutski prihvatljive soli ili njegovog solvata, u proizvodnji terapeutskog sredstva protiv bubrežne anemije.
31. Spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, za primjenu u liječenju anemije.
32. Spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegova farmaceutski prihvatljiva sol ili njegov solvat, za primjenu u liječenju bubrežne anemije.
33. Komercijalno pakiranje koje sadrži farmaceutski sastav prema patentnom zahtjevu 26 i pisano uputstvo u vezi sa njim, pri čemu je u pisanom uputstvu navedeno da se farmaceutski sastav može ili treba koristiti u liječenju profilakse bolesti izabrane od anemije i bubrežne anemije.
34. Komplet koji sadrži farmaceutski sastav prema patentnom zahtjevu 26 i pisano uputstvo u vezi sa njim, pri čemu je u pisanom uputstvu navedeno da se farmaceutski sastav može ili treba koristiti u liječenju ili profilaksi bolesti izabrane od anemije i bubrežne anemije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009169565 | 2009-07-17 | ||
| US27312709P | 2009-07-30 | 2009-07-30 | |
| PCT/JP2010/062037 WO2011007856A1 (ja) | 2009-07-17 | 2010-07-16 | トリアゾロピリジン化合物、ならびにそのプロリル水酸化酵素阻害剤およびエリスロポエチン産生誘導剤としての作用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140705T1 true HRP20140705T1 (hr) | 2014-09-12 |
Family
ID=43449466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140705AT HRP20140705T1 (hr) | 2009-07-17 | 2014-07-22 | Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8283465B2 (hr) |
| EP (3) | EP3594213A1 (hr) |
| JP (8) | JP5021797B2 (hr) |
| KR (4) | KR101850661B1 (hr) |
| CN (1) | CN102471337B (hr) |
| AR (1) | AR077417A1 (hr) |
| AU (1) | AU2010271732B2 (hr) |
| BR (1) | BR112012001157A2 (hr) |
| CA (1) | CA2768505C (hr) |
| CO (1) | CO6430426A2 (hr) |
| DK (1) | DK2455381T5 (hr) |
| ES (1) | ES2477968T3 (hr) |
| HK (1) | HK1168346A1 (hr) |
| HR (1) | HRP20140705T1 (hr) |
| IL (1) | IL217541A (hr) |
| ME (1) | ME01858B (hr) |
| MX (1) | MX2012000766A (hr) |
| MY (1) | MY160814A (hr) |
| NZ (1) | NZ598242A (hr) |
| PE (1) | PE20120629A1 (hr) |
| PL (1) | PL2455381T3 (hr) |
| PT (1) | PT2455381E (hr) |
| RS (1) | RS53499B1 (hr) |
| RU (1) | RU2538963C2 (hr) |
| SG (1) | SG178049A1 (hr) |
| SI (1) | SI2455381T1 (hr) |
| SM (1) | SMT201500122B (hr) |
| TW (1) | TWI485150B (hr) |
| WO (1) | WO2011007856A1 (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME01858B (me) * | 2009-07-17 | 2014-12-20 | Japan Tobacco Inc | Jedinjenje triazolopiridina i njegovo dejstvo kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina |
| JP2011168582A (ja) * | 2010-01-21 | 2011-09-01 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤 |
| WO2012065297A1 (en) * | 2010-11-16 | 2012-05-24 | Impact Therapeutics, Inc. | 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF |
| WO2014080640A1 (ja) | 2012-11-26 | 2014-05-30 | 国立大学法人東北大学 | エリスロポエチン発現増強剤 |
| NZ708605A (en) | 2012-12-24 | 2016-07-29 | Cadila Healthcare Ltd | Novel quinolone derivatives |
| SG10201910773VA (en) | 2013-06-13 | 2020-01-30 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| RU2534804C1 (ru) * | 2013-08-05 | 2014-12-10 | Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") | ЗАМЕЩЕННЫЕ [1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ, ПРОЯВЛЯЮЩИЕ СВОЙСТВА АНТАГОНИСТОВ АДЕНОЗИНОВЫХ А2А РЕЦЕПТОРОВ, И ИХ ПРИМЕНЕНИЕ |
| HUE036600T2 (hu) * | 2013-10-03 | 2018-07-30 | Kura Oncology Inc | ERK inhibitorok és alkalmazási eljárások |
| AU2015311333B2 (en) | 2014-09-02 | 2017-11-16 | Sunshine Lake Pharma Co., Ltd. | Quinolinone compound and use thereof |
| JP2018039733A (ja) * | 2014-12-22 | 2018-03-15 | 株式会社富士薬品 | 新規複素環誘導体 |
| GB201504565D0 (en) * | 2015-03-18 | 2015-05-06 | Takeda Pharmaceutical | Novel compounds |
| CN106146395B (zh) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3-羟基吡啶化合物、其制备方法及其制药用途 |
| JP6814134B2 (ja) * | 2015-05-28 | 2021-01-13 | 日本たばこ産業株式会社 | 糖尿病性腎症を治療又は予防する方法 |
| RU2752384C2 (ru) * | 2016-11-25 | 2021-07-26 | Джапан Тобакко Инк. | Способ получения триазолопиридинового соединения |
| WO2018205928A1 (zh) | 2017-05-09 | 2018-11-15 | 杭州安道药业有限公司 | 吲哚嗪衍生物及其在医药上的应用 |
| US10752596B2 (en) * | 2017-10-04 | 2020-08-25 | Japan Tobacco Inc. | Nitrogen-containing heteroaryl compound and pharmaceutical use thereof |
| CN107739378A (zh) * | 2017-11-14 | 2018-02-27 | 杭州安道药业有限公司 | 吲哚嗪衍生物及其在医药上的应用 |
| CN112689637B (zh) * | 2018-09-13 | 2023-11-10 | 橘生药品工业株式会社 | 咪唑并吡啶酮化合物 |
| CN110105355B (zh) * | 2019-05-24 | 2021-09-21 | 烟台大学 | 一种1,2,3-三唑-[1,5-a]并喹啉类化合物的制备方法 |
| AU2021233433A1 (en) * | 2020-03-11 | 2022-10-06 | Kissei Pharmaceutical Co., Ltd. | Crystal of imidazopyridinone compound or salt thereof |
| EP4138825A1 (en) | 2020-04-20 | 2023-03-01 | Akebia Therapeutics Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| CN113387948B (zh) * | 2021-02-06 | 2022-06-10 | 成都诺和晟泰生物科技有限公司 | 一种稠环杂芳基衍生物及其药物组合物和治疗方法及用途 |
| CN117999069A (zh) | 2021-05-27 | 2024-05-07 | 凯克斯生物制药公司 | 柠檬酸铁的儿科调配物 |
| CN113582843A (zh) * | 2021-09-09 | 2021-11-02 | 无锡捷化医药科技有限公司 | 一种5-氯-2-氟-3-羟基苯甲酸乙酯的制备方法 |
| CN114031619A (zh) * | 2021-12-17 | 2022-02-11 | 山东汇海医药化工有限公司 | 一种图卡替尼中间体的制备方法 |
| WO2024061172A1 (zh) * | 2022-09-19 | 2024-03-28 | 苏中药业集团股份有限公司 | 一种脯氨酰羟化酶抑制剂及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| JP4101755B2 (ja) * | 2001-10-08 | 2008-06-18 | エフ．ホフマン−ラ ロシュ アーゲー | ８−アミノ−〔１，２，４〕トリアゾロ〔１，５−ａ〕ピリジン−６−カルボン酸アミド |
| WO2005014533A2 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| CN1993323B (zh) * | 2004-08-05 | 2011-04-20 | 霍夫曼-拉罗奇有限公司 | 吲哚，吲唑或二氢吲哚衍生物 |
| FR2889383A1 (fr) * | 2005-08-01 | 2007-02-02 | France Telecom | Procede et dispositif de detection pour systeme mimo, systeme mimo, programme et support d'information |
| TW200808793A (en) * | 2006-03-07 | 2008-02-16 | Smithkline Beecham Corp | Prolyl hydroxylase inhibitors |
| US20090176825A1 (en) | 2006-05-16 | 2009-07-09 | Fitch Duke M | Prolyl hydroxylase inhibitors |
| PE20080209A1 (es) * | 2006-06-23 | 2008-05-15 | Smithkline Beecham Corp | Derivados de glicina como inhibidores de prolil hidroxilasa |
| SI2044005T1 (sl) * | 2006-06-26 | 2011-01-31 | Warner Chilcott Co Llc | Inhibitorji prolilhidroksilaze in postopki uporabe |
| EP2046788A1 (en) | 2006-07-12 | 2009-04-15 | Syngeta Participations AG | Triazolopyridine derivatives as herbicides |
| CL2008000066A1 (es) * | 2007-01-12 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem |
| US8048894B2 (en) | 2007-04-18 | 2011-11-01 | Amgen Inc. | Quinolones and azaquinolones that inhibit prolyl hydroxylase |
| WO2008137084A2 (en) | 2007-05-04 | 2008-11-13 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| CA2692265A1 (en) | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | Amide compounds |
| WO2009070644A1 (en) * | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US20100305133A1 (en) * | 2007-11-30 | 2010-12-02 | Smithkline Beecham Corporation | Prolyl Hydroxylase Inhibitors |
| WO2009126624A1 (en) * | 2008-04-11 | 2009-10-15 | Bristol-Myers Squibb Company | Triazolo compounds useful as dgat1 inhibitors |
| WO2009134850A1 (en) | 2008-04-30 | 2009-11-05 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| CN102112475A (zh) | 2008-05-29 | 2011-06-29 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的咪唑并吡啶和相关的类似物 |
| CN102317287B (zh) | 2008-12-19 | 2014-10-08 | 利奥制药有限公司 | 作为磷酸二酯酶抑制剂、用于治疗皮肤病的三唑并吡啶化合物 |
| ME01858B (me) * | 2009-07-17 | 2014-12-20 | Japan Tobacco Inc | Jedinjenje triazolopiridina i njegovo dejstvo kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina |
-
2010
- 2010-07-16 ME MEP-2014-82A patent/ME01858B/me unknown
- 2010-07-16 US US12/837,679 patent/US8283465B2/en active Active
- 2010-07-16 DK DK10799914.6T patent/DK2455381T5/en active
- 2010-07-16 EP EP19188636.5A patent/EP3594213A1/en not_active Withdrawn
- 2010-07-16 NZ NZ598242A patent/NZ598242A/xx unknown
- 2010-07-16 PE PE2012000056A patent/PE20120629A1/es active IP Right Grant
- 2010-07-16 SG SG2012003570A patent/SG178049A1/en unknown
- 2010-07-16 AU AU2010271732A patent/AU2010271732B2/en active Active
- 2010-07-16 KR KR1020177003353A patent/KR101850661B1/ko active IP Right Grant
- 2010-07-16 EP EP14160395.1A patent/EP2746282A1/en not_active Withdrawn
- 2010-07-16 AR ARP100102614A patent/AR077417A1/es active IP Right Grant
- 2010-07-16 ES ES10799914.6T patent/ES2477968T3/es active Active
- 2010-07-16 RS RSP20140406 patent/RS53499B1/en unknown
- 2010-07-16 WO PCT/JP2010/062037 patent/WO2011007856A1/ja active Application Filing
- 2010-07-16 KR KR1020237040564A patent/KR20230165366A/ko not_active Application Discontinuation
- 2010-07-16 PT PT107999146T patent/PT2455381E/pt unknown
- 2010-07-16 MY MYPI2012000223A patent/MY160814A/en unknown
- 2010-07-16 PL PL10799914T patent/PL2455381T3/pl unknown
- 2010-07-16 MX MX2012000766A patent/MX2012000766A/es active IP Right Grant
- 2010-07-16 EP EP10799914.6A patent/EP2455381B9/en active Active
- 2010-07-16 CN CN201080032238.2A patent/CN102471337B/zh active Active
- 2010-07-16 JP JP2010161144A patent/JP5021797B2/ja active Active
- 2010-07-16 KR KR1020187010331A patent/KR20180042443A/ko active Application Filing
- 2010-07-16 KR KR1020127004258A patent/KR101706803B1/ko active IP Right Grant
- 2010-07-16 CA CA2768505A patent/CA2768505C/en active Active
- 2010-07-16 BR BR112012001157A patent/BR112012001157A2/pt not_active Application Discontinuation
- 2010-07-16 TW TW099123410A patent/TWI485150B/zh active
- 2010-07-16 RU RU2012105467/04A patent/RU2538963C2/ru active
- 2010-07-16 SI SI201030682T patent/SI2455381T1/sl unknown
-
2012
- 2012-01-15 IL IL217541A patent/IL217541A/en active IP Right Grant
- 2012-01-31 CO CO12014916A patent/CO6430426A2/es active IP Right Grant
- 2012-04-26 JP JP2012101381A patent/JP2012144571A/ja not_active Ceased
- 2012-09-06 US US13/605,329 patent/US20130096155A1/en not_active Abandoned
- 2012-09-14 HK HK12109057.7A patent/HK1168346A1/xx unknown
-
2014
- 2014-07-22 HR HRP20140705AT patent/HRP20140705T1/hr unknown
- 2014-10-09 JP JP2014207896A patent/JP2015003933A/ja active Pending
-
2015
- 2015-05-22 SM SM201500122T patent/SMT201500122B/xx unknown
- 2015-06-25 US US14/749,966 patent/US20160145254A1/en not_active Abandoned
- 2015-12-08 JP JP2015239065A patent/JP2016040321A/ja active Pending
-
2017
- 2017-07-10 JP JP2017134270A patent/JP6434575B2/ja not_active Expired - Fee Related
-
2018
- 2018-11-08 JP JP2018210486A patent/JP2019019144A/ja active Pending
-
2020
- 2020-04-20 JP JP2020074508A patent/JP2020111612A/ja not_active Ceased
-
2022
- 2022-06-29 JP JP2022104161A patent/JP2022126843A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140705T1 (hr) | Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina | |
| RS53830B1 (en) | INDASOLS SUBSTITUTED BY OXAZOLE AS PI3-KINASE INHIBITORS | |
| JP2011037841A5 (hr) | ||
| AR082638A1 (es) | Derivados de tetrahidropiran utiles como pesticidas | |
| AR085324A1 (es) | Composiciones de moleculas pesticidas y proceso de aplicacion de dichas composiciones para controlar acaros, insectos y otras plagas | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| HRP20151410T1 (hr) | Derivati pikolinamida kao inhibitori kinaze | |
| RS51471B (en) | BIPHYNYLOXYXIC ACID DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | |
| RS54773B1 (sr) | Pirano [3,2-d][1,3] tiazol kao inhibitor glukozidaze | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| HRP20120785T1 (hr) | Spojevi i postupci za inhibiciju napredovanja mitoze putem inhibicije aurora kinaze | |
| RS54048B1 (en) | PARASITICIDE COMPOUNDS OF DIHYDROISOXAZOLE | |
| HRP20140892T1 (hr) | Novi hidroksi-6-heteroarilfenantridini i njihova uporaba kao inhibitora za pde4 | |
| WO2009112678A3 (fr) | Derives de carboxam i d es azabicycliques, leur preparation et leur application en therapeutique. | |
| EA200800476A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| HRP20110414T1 (hr) | Indoli i njihova uporaba u liječenju | |
| HRP20150305T1 (hr) | Postupak za pripravu intermedijera spojeva korisnih kao modulatori opioid receptora | |
| HN2010001460A (es) | Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion terapeutica | |
| RS54708B1 (en) | ARYLETINYL DERIVATIVES | |
| AR045083A1 (es) | Productos aril-heteroaromaticos, composiciones que los contienen y utilizacion como medicamento | |
| RS52605B (en) | Benzoic Acids (1-Phenyl-2-pyridin-4-yl) -ETHYL ESTERS AS PHOSPHODIESTERASE INHIBITORS | |
| JO2871B1 (en) | Perol compounds | |
| HRP20110289T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| RS54618B1 (en) | NEW S-NITROZOGLUTATION REDUCTASE INHIBITORS | |
| RS52964B (en) | 7-PIPERIDINOALKIL-3,4-DIHYDROKVINOLONE DERIVATIVE |